Rio Tinto Posts Strong Q4 Iron Ore and Copper Output on Operational Recovery 
Global DRAM Chip Shortage Puts Automakers Under New Cost and Supply Pressure 
Lululemon Founder Chip Wilson Escalates Proxy Fight to Remove Advent From Board 
Brazil Supreme Court Orders Asset Freeze of Nelson Tanure Amid Banco Master Investigation 
OpenAI Launches Stargate Community Plan to Offset Energy Costs and Support Local Power Infrastructure 
U.S. Vaccine Policy Shifts Under RFK Jr. Create Uncertainty for Pharma and Investors 
BHP Posts Record Iron Ore Output as China Pricing Pressures Loom 
Elon Musk Says Tesla Cybercab and Optimus Production Will Start Slowly Before Rapid Growth 
Trump Signs Executive Order to Limit Wall Street Investment in Single-Family Homes 
Valentino Garavani Dies at 93, Leaving Behind the Timeless Legacy of Valentino Red 
FAA Says It Is Not Blocking Boeing 737 MAX 7 and MAX 10 Certification 
Baidu Shares Surge After Official Launch of Advanced Ernie 5.0 AI Model 
Morgan Stanley Flags High Volatility Ahead for Tesla Stock on Robotaxi and AI Updates 
Netflix Stock Slips After Earnings as Soft 2026 Guidance Overshadows Subscriber Milestone 
BitGo IPO Prices Above Range, Raises $212.8M in Landmark Crypto Market Debut 
JPMorgan and Allen & Company Emerge as Big Winners in Warner Bros Discovery Bidding War 
NEW HAVEN, Conn., May 02, 2017 -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) announced today that Milind Deshpande, Ph.D., President and Chief Executive Officer of Achillion, will present a corporate overview at the Deutsche Bank 42nd Annual Health Care Conference on Thursday, May 4, 2017, at 10:00 a.m. ET at the Intercontinental Boston Hotel in Boston, MA.
The live audio and subsequent archived webcasts of the Company's presentations will be accessible from the Company's investor relations website, http://ir.achillion.com. The audio recording will be archived for 30 days following the live presentation. Please connect to Achillion's website several minutes prior to the start of the presentation to ensure adequate time for any software downloads that may be necessary.
About Achillion Pharmaceuticals
Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) is a science-driven, patient-focused company seeking to leverage its strengths across the continuum from discovery to commercialization in its goal of providing better treatments for people with serious diseases. The company employs a highly-disciplined discovery and development approach that has allowed it to pursue best-in-class oral antiviral therapy for chronic hepatitis C (HCV) and build a platform of potent and specific complement factor D inhibitors for AP-mediated diseases. Achillion is rapidly advancing its efforts to become a fully-integrated pharmaceutical company with a goal of bringing life-saving medicines to patients with rare diseases. More information is available at http://www.achillion.com.
Investors & Media: Glenn Schulman Achillion Pharmaceuticals, Inc. Tel. (203) 752-5510 [email protected]
